

# Pro- & retrosp. Register

oligometastasiertes  
Pankreaskarzinom

Thomas Brunner

Universitätsklinik für Strahlentherapie-Radioonkologie

Medizinische Universität Graz

Graz  
DEGRO AG  
07.02.2026

# Evidence

ORIGINAL ARTICLE

# **Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer**

## **A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT**

**E. Gkika<sup>1</sup> · S. Adebahr<sup>1,5</sup> · S. Kirste<sup>1</sup> · T. Schimek-Jasch<sup>1</sup> · R. Wiehle<sup>4</sup> · R. Claus<sup>2</sup> · U. Wittel<sup>3</sup> · U. Nestle<sup>1,5,6</sup> · D. Baltas<sup>4,5,6</sup> · A. L. Grosu<sup>1,5,6</sup> · T. B. Brunner<sup>1,5,6</sup>**

# Oligometastasiertes Pankreaskarzinom

*Ludmir EB et al., J Clin Oncol. 2024 Aug 4; JCO2400081 ahead of print*


## Text

Original Reports | Gastrointestinal Cancer

# Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial


# CONSORT-Diagramm

*Ludmir EB et al., J Clin Oncol. 2024 Aug 4; JCO2400081 ahead of print*




# CONSORT-Diagramm

*Ludmir EB et al., J Clin Oncol. 2024 Aug 4; JCO2400081 ahead of print*



# Folientitel

*Ludmir EB et al., J Clin Oncol. 2024 Aug 4; JCO2400081 ahead of print*



# Patientencharakteristika: ausgeglichen

*Ludmir EB et al., J Clin Oncol. 2024 Aug 4; JCO2400081 ahead of print*

Characteristic	MDT Arm	Control Arm
Age, years, median (min-max)	68 (31-84)	67 (45-75)
Gender, No. (%)		
Female	10 (53)	8 (38)
Male	9 (47)	13 (62)
Race, No. (%)		
Asian	1 (5)	1 (5)
Black or African American	1 (5)	6 (29)
White or Caucasian	17 (89)	14 (67)
Ethnicity, No. (%)		
Hispanic or Latino	2 (11)	1 (5)
Not Hispanic or Latino	17 (89)	19 (90)
Unknown	0	1 (5)
Number of metastatic lesions, No. (%)		
1-2	15 (79)	16 (76)
3-5	4 (21)	5 (24)
Sites of metastatic disease, <sup>a</sup> No. (%)		
Lung	6 (32)	4 (19)
Liver	11 (58)	15 (71)
Nonregional lymph node	2 (11)	1 (5)
Bone	2 (11)	0
Other <sup>b</sup>	0	2 (10)
Lung-limited disease, No. (%)	1 (5)	2 (10)
Previous lines of systemic therapy for metastasis with progression, No. (%)		
0	10 (53)	15 (71)
1	9 (47)	4 (19)
2	0	2 (10)
Cancer antigen 19-9, No. (%)		
<90 U/mL	10 (53)	11 (52)
≥90 U/mL	9 (47)	10 (48)
Oligometastasis state, No. (%)		
Synchronous	7 (37)	7 (33)
Metachronous	12 (63)	14 (67)
Induced oligometastasis from polymetastasis	0	0
Primary tumor not previously treated by local therapy, <sup>c</sup> No. (%)	11 (58)	12 (57)
Time from initial diagnosis to enrollment, months, median (min-max)	12 (5-29)	9 (4-88)
Time from metastatic diagnosis to enrollment, months, median (min-max)	4 (0.1-15)	5 (0.3-25)


# Patientencharakteristika: Auswahl

*Ludmir EB et al., J Clin Oncol. 2024 Aug 4; JCO2400081 ahead of print*

Parameter	MDT-Arm	Kontrolle
Number of metastatic lesions, No. (%)		
1-2	15 (79)	16 (76)
3-5	4 (21)	5 (24)
Sites of metastatic disease, <sup>a</sup> No. (%)		
Lung	6 (32)	4 (19)
Liver	11 (58)	15 (71)
Nonregional lymph node	2 (11)	1 (5)
Bone	2 (11)	0
Other <sup>b</sup>	0	2 (10)
Lung-limited disease, No. (%)		
	1 (5)	2 (10)
Previous lines of systemic therapy for metastasis with progression, No. (%)		
0	10 (53)	15 (71)
1	9 (47)	4 (19)
2	0	2 (10)
Cancer antigen 19-9, No. (%)		
<90 U/mL	10 (53)	11 (52)
≥90 U/mL	9 (47)	10 (48)

# EXTEND: Progressionsfreies Überleben

Ludmir EB et al., J Clin Oncol. 2024 Aug 4; JCO2400081 ahead of print




No. at risk (events)

Control group	21	(18)	1	(0)	0
MDT	19	(10)	5	(3)	0

# EXTEND: Gesamtüberleben

Ludmir EB et al., J Clin Oncol. 2024 Aug 4; JCO2400081 ahead of print




No. at risk (events)

Control group	21	(10)	6	(2)	1
MDT	20	(8)	8	(4)	1

# Swimmer Plot: Progress


*Ludmir EB et al., J Clin Oncol. 2024 Aug 4; JCO2400081 ahead of print*



# Fazit für die Klinik und Praxis

- **Das Prinzip der oligometastatischen Metastasen gerichteten Therapie zeigt für das PFS nach SBRT gute Evidenz in der Phase II-Situation**
- **Weitere Studien müssen folgen**

# OligoPanc Project: Delphi Process



(submitted)

# The OligoPanc Project: Parameters of 16 Vignettes


Parameter	
Age	
ECOG	
CA19-9	(pre-Tx)
CEA	(pre-Tx)
Resectability /	Final pathology
Location	metastasis
Total number of metastasis	

Parameter	
Clinical Scenario*	
DFS	
Treatment Response	


\*Guckenberger M et al. Characterisation and classification of oligometastatic disease: a ESTRO and EORTC consensus recommendation. The Lancet Oncology. 2020;21(1):e18-e28.

Leonhardt CS et al. (submitted)

# Does this patient have oligometastatic PDAC?



# Which liver directed therapy in addition to systemic?



# The OligoPanc Project: An Interdisciplinary Expert Consensus Statement on Oligometastatic Pancreatic Cancer

metachronous metastases (vignettes 12, 13, 15, 16):

**SBRT was most commonly recommended**

# The OligoPanc Project: Conclusions

- 18 Konsenspunkte identifiziert
- omPDAC =  $\leq 3$  synchrone oder metachrone Metastasen in der Leber oder der Lunge
- Entscheidung des Tumorboards ist für Diagnose und Therapieentscheidung unerlässlich
- Möglichkeit einer lokalen Konsolidierungstherapie zusätzlich zur systemischen Therapie ist wichtig für die Behandlung des omPDAC

# POLARBEAR Register

## Struktur und Design des Registers

- sowohl retrospektiv als auch prospektiv
- genaue Erfassung der Daten
- langjährige Erfahrung in der SBRT des Abdomens und der Lunge
- nach den entsprechenden Richtlinien der Fachgesellschaft durchführen (Sterzing et al. 2014; Brunner et al. 2025)



JAREDANDLINDSAY.COM  
© 2012 LINDSAY CIBOS

# POLARBEAR Register

## Zeitplan

- **retrospektive** Datenerhebung: wird im Juni 2026 eröffnet.
- Datenerhebung für ein Jahr: retrospektive Datenerfassung bis zum 01.07.2027 abgeschlossen
- **prospektive** Datenerhebung: Rekrutierung vom 01.06.2026 bis zum 31.12.2027 vorgesehen.
- Plus FU für 24 weitere Monate nach Behandlungsende



JAREDANDLINDSAY.COM  
© 2012 LINDSAY CIBOS

# Vielen Dank für Ihre Aufmerksamkeit!

